Semma Therapeutics has closed an oversubscribed $114 million Series B round to help fund the development of its encapsulated stem cell-derived islet therapy for Type I diabetes. The Cambridge, Mass.-based company reported that it plans to use the newly-acquired funds to bring its cell therapy through clinical proof-of-concept studies, as well as explore other regenerative medicine […]
Semma Therapeutics
Artificial pancreas: These companies are racing to make one
Medical device companies are close to achieving the holy grail of diabetes treatment: a combined glucose sensor, control algorithm and insulin infusion device that effectively acts as an “artificial pancreas.” We explain more in the newest video from editors at MassDevice’s sister publication Medical Design & Outsourcing. (And for a deeper dive, check out our recent […]
Defymed partners with Semma Therapeutics on bio-artificial pancreas
French biotech developer Defymed said today it inked a collaborative deal with American biotech company Semma Therapeutics to support the continued development of a bio-artificial pancreas to treat type-1 diabetes. The collaborative deal will aim to achieve pre-clinical validation of Defymed’s Mailpan bio-artificial pancreas in combination with Semma’s stem-cell derived differentiated insulin-secreting cells, Defymed said. The Mailpan device […]
OSP fishes up $11m | Medtech funding for the week of March 23, 2015
Diabetes: Medtronic joins $44m round for Semma Therapeutics
